NEW YORK (GenomeWeb News) — DSM Venturing has invested €2 million ($2.7 million) in Finnish diagnostics company Jurilab, DSM said today.
Jurilab specializes in disease markers and pathways, drug targets, and diagnostic content for metabolic syndrome. DSM, a financing branch of the Dutch company Royal DSM, said it believes that Jurilab’s access to the “relatively homogenous” East Finland founder population and its databank make its approach “faster, more informative, and more cost-effective than many traditional screening approaches."
Metabolic syndrome is sometimes used as an umbrella term to cover obesity, type 2 diabetes, dyslipidemia, and hypertension, DSM said. The market for diagnostics and personalized approaches to these diseases will continue to grow as populations age and become more health conscious, DSM said.
DSM last year put $2.6 million into its nutrigenomics programs through an investment in molecular diagnostics company Integragen.